Epi Data Slicer
Epi Data Slicer
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…
Clarivate Epidemiology's coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for…